Bridget Phillipson

“When Dr Hilary Cass published her review, we endorsed all those recommendations, as did the Conservatives. An important part of what Dr Cass set out was that it is essential that healthcare is available to children and young people who are experiencing gender dysphoria or incongruence, but that it must be safe, evidence-based and clinically appropriate. We have always been clear about the red lines regarding the Medicines and Healthcare products Regulatory Agency’s trial and the prescription of puberty blockers, and the safety and wellbeing of children must be at the forefront of everything that we do, but the review by Dr Cass concluded that while not enough was known about the safety of puberty-suppressing hormones, it was necessary to take forward a trial.”